Full-text access for premium subscribers only. Existing premium subscribers login here . New to GenomeWeb? Register quickly here . Genome Technology's Tracy Vence interviewed Sandra Porter , president of Digital World Biology, and Kristi Holmes , a bioinformaticist at the Becker Medical Library, Washington University School of Medicine at ScieneOnline2012.
Full-text access for premium subscribers only. Existing premium subscribers login here . New to GenomeWeb? Register quickly here . Sage Science is pleased to announce the introduction of the BluePippin DNA size selection system, a pulsed-field electrophoresis version of its popular Pippin Prep instrument.
(RTTNews.com) – Myriad Genetics Inc. (MYGN) Tuesday reported a 17 percent rise in second-quarter earnings on double-digit revenue growth at Molecular diagnostic testing segment and contribution of Companion diagnostic acquired last May. Both earnings and revenue for the quarter topped analysts estimates.
Looking ahead, the company also raised its outlook for full year 2012. Buoyed by the results, Myriad Genetics shares gained more than 5 percent in extended trade on the Nasdaq.
Net income for the second quarter rose to $28.3 million or $0.33 per share from $24.2 million or $0.26 per share in the prior year. On average, 19 analysts polled by Thomson Reuters expected earnings of $0.31 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues for the quarter grew 22 percent to $123 million from $100.4 million a year ago. Analysts expected revenues of $115.29 million.
Molecular diagnostic testing revenue grew 17 percent and accounted for most of the revenues, as all segments and products saw growth. Within the segment, Oncology revenue rose 15 percent, and Women's Health revenue by 22 percent. Revenue from Companion diagnostic service was $5.2 million.
Myriad Genetics now expects 2012 earnings in a range of $1.24 to $1.28 per share and revenues of $465 million to $475 million. Analysts currently expect earnings of $1.24 per share and revenues of $461.45 million for the year.
The company had earlier forecast 2012 earnings in the range of $1.20 to $1.25 per share with revenues of $465 million to $475 million.
Salt Lake City, Utah-based Myriad Genetics is a molecular diagnostic company that focuses on the development of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the U.S.
MYGN closed Tuesday on the Nasdaq at $23.66, up $0.40 or 1.72%, on a volume of about 1.8 million shares. In after hours, the stock further gained $1.24 or 5.24%.
For comments and feedback: contact editorial@rttnews.com
SALT LAKE CITY — Myriad Genetics, Inc. today announced results for its second fiscal quarter and six months ending December 31, 2011. Revenue for the second fiscal quarter was $122.8 million, an increase …
Washington, Jan 27 : An available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods, according to a team of scientists.
Scientists from the University of California San Francisco, Kaiser Permanente, and China have teamed up to study a molecular test that could give more patients a chance to be cured of lung cancer.
In a finding that could improve the survival odds for early-stage lung cancer patients, UCSF researchers determined a new molecular test can predict more accurately than current diagnostic methods which tumors are more…
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods.
( University of Chicago Medical Center ) The University of Chicago's Janet Rowley will share the 2012 Japan Prize for Healthcare and Medical Technology with Brian Druker, OHSU, and Nicholas Lydon, Ph.D., Novartis, for their roles in the development of the first precisely targeted anti-cancer drug, Gleevec.
Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced the appointment of Christoph Lengauer, Ph.D., as chief scientific officer.
05-01-2012 15:46 Humans are intensely social beings that have evolved and developed within highly social environments in which each individual is dependent upon others. We constantly engage in social perception, using cues from facial expressions, gaze shifts, and body movements, to infer the intentions of others and plan our own actions accordingly. Kevin Pelphrey investigates the properties of specialized brain systems that are important for social perception using functional magnetic resonance imaging (fMRI), eye tracking, and molecular genetics in typically developing adults and children, as well as in children and adults with autism.
12-12-2011 16:34 Janet Rowley, MD, sparked a revolution in cancer genetics and continues to shape the field of personalized medicine today. Rowley and her fellow University of Chicago colleagues, Michelle LeBeau, PhD, director, University of Chicago Comprehensive Cancer Center; Vinay Kumar, MBBS, MD, chair, Department of Pathology; and Richard Schilsky, MD, chief, Section of Hematology/Oncology; talk about this groundbreaking research and current advances in targeted therapy for cancer care.
05-12-2011 07:48 Expand me! Fringe’s video: www.youtube.com Part 1 of the series: www.youtube.com Fringe, this is quickly turning from a conflict of genetics vs. racism into a conflict of true education and access to knowledge vs. ignorance and access to Google
02-12-2011 10:15 Ravi Jhaveri, MD, is an assistant professor of pediatrics and molecular genetics and microbiology at Duke. His work focuses on children with viral hepatitis (A, B, and C) and general pediatric infectious diseases.
28-10-2011 08:08 On Thursday, October 27, 2011, a panel of Duke faculty members, and a postdoc who was successful on the academic job market (20 applications, 7 interviews, 3 offers), discussed the negotiation process. Questions included: – What does a typical start-up package look like? How much can you negotiate it, and how can you provide justification for asking for more